SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
Researchers have found that having higher IGF-1 levels puts all ages at higher risk of developing cancer. For older people, ...
Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the presentation of ...
Lirum Therapeutics Inc. has presented data regarding their insulin-like growth factor receptor (IGF-1R) antagonist LX-101, which couples an IGF-1 variant to a cytotoxic methotrexate payload. The ...
("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and ...
a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody) for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug ...